Status and phase
Conditions
Treatments
About
This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Junliang Fu, PhD, MD; Fu-Sheng Wang, PhD, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal